![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Nuformix Plc | LSE:NFX | London | Ordinary Share | GB00BYW79Y38 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.175 | 0.15 | 0.20 | 377,843 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -859k | -0.0010 | -1.70 | 1.43M |
TIDMNFX
RNS Number : 6304J
Nuformix PLC
24 August 2021
Nuformix plc
("Nuformix" or the "Company")
Results of Annual General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that all resolutions proposed at its Annual General Meeting held today were duly passed. The results are set out below:
The Q&A for AGM will be available on the website later this week.
Resolution Ordinary/ For Against Total votes Special cast No. of % No. of % votes votes ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To receive the annual report and accounts for the year ended 1 31 March 2021 Ordinary 41,314,178 99.97% 10,888 0.03% 41,325,066 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To approve the Remuneration 2 Policy Ordinary 40,759,964 98.58% 586,866 1.42% 41,346,830 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To re-appoint Annual 3 Report on Remuneration Ordinary 40,862,374 98.88% 462,692 1.12% 41,325,066 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To re-appoint Alastair 4 Riddell as a director Ordinary 40,811,768 98.71% 531,941 1.29% 41,343,709 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To re-appoint Julian 5 Gilbert as a director Ordinary 41,211,768 99.68% 131,941 0.32% 41,343,709 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To re-appoint s Madeleine Kennedy 6 as a director Ordinary 41,162,427 99.56% 181,282 0.44% 41,343,709 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To re-appoint Anne 7 Brindley as a director Ordinary 40,811,768 98.71% 531,941 1.29% 41,343,709 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To re-appoint haysmacintyre 8 as auditor Ordinary 41,211,768 99.97% 10,888 0.03% 41,222,656 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To authorise the Directors to determine 9 the auditor's fees. Ordinary 40,953,492 99.05% 393,338 0.95% 41,346,830 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To authorise the Directors to allot 10 shares. Ordinary 40,362,427 97.50% 1,036,813 2.50% 41,399,240 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To authorise the Directors to disapply 11 pre-emption rights. Special 39,584,831 95.50% 1,864,409 4.50% 41,449,240 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To authorise the Company to purchase 12 its own shares. Special 41,286,601 99.61% 162,639 0.39% 41,449,240 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------ To authorise calling of a general meeting on 14 clear days' 13 notice. Special 41,438,352 99.97% 10,888 0.03% 41,449,240 ----------------------------------- ---------- ----------- ------- ---------- ------ ------------
(1) A vote withheld is not a vote under English law and is therefore not included in the calculation of votes for and against a resolution.
In accordance with Listing Rule 9.6.2, a copy of all resolutions passed as special business will
shortly be available for inspection at the National Storage Mechanism document viewing facility
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
Enquiries:
Nuformix plc via Walbrook Dr Alastair Riddell, Non-Executive Chairman Dr Anne Brindley, CEO Allenby Capital Limited +44 (0) 20 3328 5656 Nick Athanas / George Payne (Corporate Finance) Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) Walbrook PR nuformix@walbrookpr.com or +44 (0)20 7933 87 80 Anna Dunphy / Phillip Marriage Tel: +44 (0)7876 741 001 / +44 / Kiki Zaccagnini (0)7980 541 893
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.
For more information, please visit www.nuformix.com .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGBZLFLFVLEBBE
(END) Dow Jones Newswires
August 24, 2021 06:57 ET (10:57 GMT)
1 Year Nuformix Chart |
1 Month Nuformix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions